Current Treatment Options in Gastroenterology

, Volume 6, Issue 4, pp 299–309 | Cite as

Idiopathic and diabetic gastroparesis

  • Deirdre O’Donovan
  • Christine Feinle-Bisset
  • Karen Jones
  • Michael Horowitz

Opinion statement

The management of both diabetic and idiopathic gastroparesis often represents a substantial clinical challenge. In formulating recommendations for therapy, it should be recognized that these are based on less than optimal evidence; in particular, there are substantial deficiencies in current knowledge relating to the pathophysiology of gastroparesis, as well as the natural history of gastrointestinal symptoms, and the majority of pharmacologic trials have been short term and associated with methodologic limitations. Although the etiologic factors differ, the overall management principles are similar in the two conditions. Maintenance of adequate nutrition is pivotal, and parenteral nutrition may be required in severe cases associated with malnutrition. In patients with diabetes, rigorous attempts should be made to optimize glycemic control —hyperglycemia slows gastric emptying and may exacerbate symptoms and attenuate the effects of prokinetic drugs. Despite the relatively poor predictive value of symptoms, it is reasonable to suggest a trial of prokinetic therapy for about 4 weeks, rather than initially establishing the diagnosis by measurement of gastric emptying. However, it should be recognized that there is a substantial placebo response, a lack of evidence to support the cost effectiveness of such an approach, and that most patients will require prolonged therapy. In type 1 diabetic patients, prokinetic therapy may potentially benefit glycemic control, and this forms an additional rationale (albeit not established) for therapy. Some patients with diabetes and idiopathic gastroparesis with severe vomiting are unable to tolerate oral medication; in such cases subcutaneous metoclopramide may prove useful. Patients with intractable symptoms should be hospitalized and given intravenous erythromycin. The repertoire of prokinetic agents available in the United States is limited and includes metoclopramide, erythromycin, and cisapride (available by special program from its manufacturer); all of these drugs are associated with side effects. The use of metoclopramide may represent the first choice for chronic oral therapy, although it has been studied less comprehensively than cisapride. Combination therapy may be potentially more efficacious than the use of single agents. Dehydration and metabolic derangements should be corrected. The choice of chronic medical therapy should be individualized, taking factors such as age, presence of diabetes, concurrent medications, and comorbidities into account. In a small number of patients in whom medical treatment fails, surgery should be considered, and, if performed, done in a specialized center. A number of novel therapies, including gastric electrical stimulation, are currently being evaluated.


Gastric Emptying Metoclopramide Cisapride Gastroparesis Domperidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Domstad PA, Kim EE, Coupal JJ, et al.: Biologic gastric emptying time in diabetic patients, using Tc-99mlabeled resin-oatmeal with and without metoclopramide. J Nucl Med 1980, 21:1098–1100.PubMedGoogle Scholar
  2. 2.
    Horowitz M, Harding PE, Maddox AF, et al.: Gastric and oesophageal emptying in patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1989, 32:151–159.PubMedCrossRefGoogle Scholar
  3. 3.
    Horowitz M, Maddox AF, Wishart JM, et al.: Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991, 18:229–234.PubMedCrossRefGoogle Scholar
  4. 4.
    Stanghellini V, Tosetti C, Paternico A, et al.: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110:1036–1042.PubMedCrossRefGoogle Scholar
  5. 5.
    Tougas G, Chen Y, Coates G, et al.: Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000, 95:78–86.PubMedCrossRefGoogle Scholar
  6. 6.
    Holzapfel A, Festa A, Stacher-Janotta G, et al.: Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia 1999, 42:1410–1412.PubMedCrossRefGoogle Scholar
  7. 7.
    Stacher G, Bergmann H, Gaupmann G, et al.: Fat preload delays gastric emptying: reversal by cisapride. Br J Clin Pharmacol 1990, 30:839–845.PubMedGoogle Scholar
  8. 8.
    Rayner CK, Samsom M, Jones KL, et al.: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371–381. A comprehensive and well-summarized review outlining the complex interaction between glycemic control and gut motor and sensory function.PubMedCrossRefGoogle Scholar
  9. 9.
    Rabine JC, Barnett JL: Management of the patient with gastroparesis. J Clin Gastroenterol 2001, 32:11–18. An excellent review of current management approaches.PubMedCrossRefGoogle Scholar
  10. 10.
    Horowitz M, O’Donovan D, Jones KL, et al.: Gastric emptying in diabetes: clinical significance and treatment. Diabetes Med 2002, 19:177–194. Highlights specific issues relating to the management of diabetic gastroparesis.CrossRefGoogle Scholar
  11. 11.
    Camilleri M, Balm RK, Zinsmeister AR: Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994, 106:916–923.PubMedGoogle Scholar
  12. 12.
    Weber FH Jr, Richards RD, McCallum RW: Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993, 88:485–490.PubMedGoogle Scholar
  13. 13.
    Camilleri M: The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol 1993, 88:169–171.PubMedGoogle Scholar
  14. 14.
    Richards RD, Davenport K, McCallum RW: The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993, 88:203–207.PubMedGoogle Scholar
  15. 15.
    DiBaise JK, Quigley EM: Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center’s experience. J Clin Gastroenterol 1999, 28:131–134.PubMedCrossRefGoogle Scholar
  16. 16.
    Petrakis IE, Vrachassotakis N, Sciacca V, et al.: Hyperglycemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999, 34:396–403.PubMedCrossRefGoogle Scholar
  17. 17.
    Camilleri M: Advances in diabetic gastroparesis. Rev Gastroenterol Disord 2002, 2:47–56. Comprehensive and well-summarized review.PubMedGoogle Scholar
  18. 18.
    Desautels SG, Hutson WR, Christian PE, et al.: Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Dig Dis Sci 1995, 40:141–146.PubMedCrossRefGoogle Scholar
  19. 19.
    Ehrenpreis ED, Zaitman D, Nellans H: Which form of erythromycin should be used to treat gastroparesis? A pharmacokinetic analysis. Aliment Pharmacol Ther 1998, 12:373–376.PubMedCrossRefGoogle Scholar
  20. 20.
    Quigley EM: Pharmacotherapy of gastroparesis. Expert Opin Pharmacother 2000, 1:881–887.PubMedCrossRefGoogle Scholar
  21. 21.
    Dutta U, Padhy AK, Ahuja V, et al.: Double blind controlled trial of effect of cisapride on gastric emptying in diabetics. Trop Gastroenterol 1999, 20:116–119.PubMedGoogle Scholar
  22. 22.
    Horowitz M, Maddox A, Harding PE, et al.: Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987, 92:1899–1907.PubMedGoogle Scholar
  23. 23.
    Abell TL, Camilleri M, DiMagno EP, et al.: Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991, 36:616–620.PubMedCrossRefGoogle Scholar
  24. 24.
    Veysey MJ, Malcolm P, Mallet AI, et al.: Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial. Gut 2001, 49:828–834.PubMedCrossRefGoogle Scholar
  25. 25.
    Tonini M: Polyethylene glycol as a non-absorbable prokinetic agent in the lower gastrointestinal tract. Ital J Gastroenterol Hepatol 1999, 31(suppl3):S238-S241.PubMedGoogle Scholar
  26. 26.
    Evans AJ, Krentz AJ: Should cisapride be avoided in patients with diabetic gastroparesis? J Diabetes Complications 1999, 13:314–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Tonini M, DePonti F, DiNucci A, et al.: Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999, 13:1585–1591.PubMedCrossRefGoogle Scholar
  28. 28.
    McHugh S, Lico S, Diamant NE: Cisapride vs metoclopramide —an acute study in diabetic gastroparesis. Dig Dis Sci 1992, 37:997–1001.PubMedCrossRefGoogle Scholar
  29. 29.
    Loo FD, Palmer DW, Soergel KH, et al.: Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984, 86:485–494.PubMedGoogle Scholar
  30. 30.
    Ganzini L, Casey DE, Hoffman WF, et al.: The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469–1475.PubMedCrossRefGoogle Scholar
  31. 31.
    Bentsen G, Stubhaug A: Cardiac arrest after intravenous metoclopramide—a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest. Acta Anaesthesiol Scand 2002, 46:908–910.PubMedCrossRefGoogle Scholar
  32. 32.
    Takahashi T, Kurosawa S, Wiley JW, et al.: Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991, 101:703–710.PubMedGoogle Scholar
  33. 33.
    Farup CE, Leidy NK, Murray M, et al.: Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998, 21:1699–1706.PubMedCrossRefGoogle Scholar
  34. 34.
    Daaboul B, Sarosiek I, Lin Z, et al.: Combination therapy of cisapride and domperidone: its effect on gastrointestinal symptoms and overall health status in patients with gastroparesis [abstract]. Am J Gastroenterol 1999, 94:2624.CrossRefGoogle Scholar
  35. 35.
    Kim CH, Nelson DK: Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endoscopy 1998, 47:67–70.CrossRefGoogle Scholar
  36. 36.
    Mathus-Vliegen LM, Koning H: Percutaneous endoscopic gastrostomy and gastrojejunostomy: a critical reappraisal of patient selection, tube function and the feasibility of nutritional support during extended follow-up. Gastrointest Endoscopy 1999, 50:746–754.CrossRefGoogle Scholar
  37. 37.
    Yamashita S, Yamaguchi H, Sakaguchi M, et al.: Longerterm diabetic patients have a more frequent incidence of nosocomial infections after elective gastrectomy. Anesth Analg 2000, 91:1176–1181.PubMedCrossRefGoogle Scholar
  38. 38.
    Gaber AO, Oxley D, Karas J, et al.: Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis 1991, 9:437–443.PubMedCrossRefGoogle Scholar
  39. 39.
    McCallum RW, Chen JD, Lin Z, et al.: Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998, 114:456–461.PubMedCrossRefGoogle Scholar
  40. 40.
    Tougas G, Huizinga JD: Gastric pacing as a treatment for intractable gastroparesis: shocking news? Gastroenterology 1998, 114:598–601.PubMedCrossRefGoogle Scholar
  41. 41.
    Mintchev MP, Sanmiguel CP, Amaris M, et al.: Microprocessor-controlled movement of solid gastric content using sequential neural electrical stimulation. Gastroenterology 2000, 118:258–263.PubMedCrossRefGoogle Scholar
  42. 42.
    Lacy BE, Zayat EN, Crowell MD, et al.: Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002, 97:1548–1552.PubMedCrossRefGoogle Scholar
  43. 43.
    Miller LS, Szych GA, Kantor SB, et al.: Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002, 97:1653–1660.PubMedCrossRefGoogle Scholar
  44. 44.
    Schwizer W, Borovicka J, Kunz P, et al.: Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997, 41:500–504.PubMedCrossRefGoogle Scholar
  45. 45.
    Talley NJ, Verlinden M, Geenen DJ, et al.: Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001, 49:395–401.PubMedCrossRefGoogle Scholar
  46. 46.
    Watkins CC, Sawa A, Jaffrey S, et al.: Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000, 106:373–384.PubMedCrossRefGoogle Scholar
  47. 47.
    Chang CS, Ko CW, Wu CY, et al.: Effect of electrical stimulation on acupuncture points in diabetic patients with gastric dysrhythmia: a pilot study. Digestion 2001, 64:184–190.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Deirdre O’Donovan
    • 1
  • Christine Feinle-Bisset
    • 1
  • Karen Jones
    • 1
  • Michael Horowitz
    • 1
  1. 1.Department of MedicineUniversity of AdelaideAdelaideAustralia

Personalised recommendations